The global vaccine adjuvants market consists of human and
veterinary adjuvants that are used to improve the efficacy of vaccines. This
market is driven by several factors such as increasing government funding for
research, high prevalence of diseases, expanding biotechnology and
biopharmaceutical industries, and growing focus on the prevention of diseases.
The global vaccine adjuvants market is expected to reach USD
769.4 Million by 2021 from USD 467.0 Million in 2016, at a CAGR of 10.5%.
Get a sample PDF copy of the Report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894
The research applications segment is expected to account for
the largest share of the market during the forecast period. The human vaccine
adjuvants segment is expected to account for the largest share of the global
market in 2016 and is expected to have a higher growth rate in the application
category segment.
What Drives the Market?
1. Increasing Use of Adjuvants in Vaccine
2. High Prevalence of Infectious and Zoonotic Diseases
3. Increase in Livestock and Instances of Diseases
4. Increasing Focus on Immunization Programs From Various Government
Bodies
5. Technological Advancements in Aluminum Hydroxide-Based
Adjuvants
The global market is broadly classified into product type,
route of administration, disease type, applications, and application
categories.
On the basis of product type, the vaccine adjuvants market
is segmented into pathogen components, adjuvant emulsions, particulate
adjuvants, combination adjuvants, and others. The particulate adjuvants segment
is expected to account for the largest share of the global market in 2016.
Target Audience for this Report:
# Vaccine adjuvants manufacturers and suppliers
# Academic research institutes
# Biopharmaceutical and biotechnology companies
# Research and development (R&D) companies
# Business research and consulting service providers
# Medical research laboratories
# Academic medical centers and universities
On the basis of disease type, the vaccine adjuvants market
is segmented into infectious diseases, cancer, and others. The infectious
diseases segment is expected to account for the largest share of the global
market in 2016. Factors such as high prevalence of infectious diseases,
government & company initiatives, and high prevalence of cancer cases are
expected to drive market growth in the coming years.
The geographical regions mapped in the report are:
1. North America
2. Europe
3. Asia-Pacific
4. Rest of the World (RoW)
The vaccine adjuvants market is dominated by North America,
followed by Europe, Asia, and the Rest of the World (RoW). However, Asia is
projected to grow at the highest CAGR during the forecast period. Growth in the
North American segment is primarily driven by the increasing geriatric
population and rising incidences of diseases in the North American countries
Some key players mentioned in the research report are:
Brenntag Biosector (Denmark), CSL Limited (Australia),
SEPPIC (France), Agenus, Inc. (U.S.), Novavax, Inc. (U.S.), SPI Pharma, Inc.
(U.S.), Invivogen (U.S.), Avanti Polar Lipids, Inc. (U.S.), MVP Laboratories,
Inc. (U.S.), and OZ Biosciences (France).
MarketsandMarkets™ provides quantified B2B research on
30,000 high growth emerging opportunities/threats which will impact 70% to 80%
of worldwide companies' revenues. Currently servicing 7500 customers worldwide
including 80% of global Fortune 1000 companies as clients. Almost 75,000 top
officers across eight industries worldwide approach MarketsandMarkets™ for
their pain-points around revenues decisions.